- Research article
- Open Access
Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model
BMC Research Notes volume 9, Article number: 80 (2016)
Enteric and diarrheal diseases are important causes of childhood death in the developing world. These diseases are responsible for more than 750 thousand deaths in children under 5 years old worldwide, ranking second cause of death, after lower respiratory diseases, in this age group. Among the major causative agents of diarrhea is Escherichia coli. There are several vaccine trials for diarrheagenic E. coli. However, diarrheagenic E. coli has seven pathotypes and vaccines are directed for one or two of the five main pathotypes-causing diarrhea. Currently, there are no combined vaccines available in the market for all five diarrheagenic E. coli pathotypes. Therefore, we aimed to develop a low-cost vaccine candidate combining the five main diarrheagenic E. coli to offer wide-spectrum protection. We formulated a formalin-killed whole-cell mixture of enteroaggregative, enteropathogenic, enteroinvasive, enterohemorrhagic, and enterotoxigenic E. coli pathotypes as a combined vaccine candidate.
We immunized Balb/C mice subcutaneously with 109 CFU of combined vaccine candidate and found a significant increase in survival rate post challenge compared to unimmunized controls (100 % survival). Next we aimed to determine the immunological response of mice to the combined vaccine candidate compared to each pathotype immunization. To do so, we immunized mice groups with combined vaccine candidate and monitored biomarkers levels over 6 weeks as well as measured responses post challenge with relevant living E. coli. We found significant increase in specific systemic antibodies (IgG), interferon gamma (IFNγ) and interleukin 6 (IL-6) levels elicited by combined vaccine candidate especially in the first 2 weeks after mice immunization compared to controls (p < 0.05). We also evaluated alum and cholera toxin B subunit (CTB) as potential adjuvant systems for our candidate vaccine. We found that CTB-adjuvanted combined vaccine candidate showed significantly higher IgG and IFNγ levels than alum.
Overall, our combined vaccine candidate offered protection against the five main diarrheagenic E. coli pathotypes in a single vaccine using mouse model. To the best of our knowledge, this is the first combined vaccine against the five main diarrheagenic E. coli pathotypes that is cost-effective with promise for further testing in humans.
Diarrhea is a major public health problem that usually lasts a day or two and often disappears without any special treatment. However, prolonged diarrhea can cause severe dehydration and even death . One of the causative agents of diarrhea is Escherichia coli. There are several pathotypes of E. coli that cause infections of the gastrointestinal system while other pathotypes cause infections outside the gastrointestinal system as bacteremia, nosocomial pneumonia and neonatal meningitis .
Diarrheagenic E. coli can be categorized into subgroups including enterotoxigenic E. coli (ETEC) that affects small intestine [2, 3]. ETEC is a major cause of traveler diarrhea and is responsible for 280 million diarrheal episodes and more than 400 thousand death annually . Enteropathogenic E. coli (EPEC) affects small intestine and is responsible for infant diarrhea with fever, nausea and vomiting. Enterohaemorrhagic E. coli (EHEC) affects large intestine and leads to severe abdominal pain, watery diarrhea followed by bloody diarrhea leading to hemolytic uremic syndrome [2, 3]. Enteroinvasive E. coli (EIEC) affects large intestine and produce shigella-like diarrhea and is responsible for tissue invasion and destruction of epithelial cells [2, 3]. The fifth and final subgroup is enteroaggregative E. coli (EAEC), which affects small intestine and is responsible for endemic diarrhea of infants in both industrialized and developing countries [4, 5].
In diseases caused by E. coli, current treatments do not cure the infection, but are directed to relieve symptoms or prevent complications. Treatment includes rest and fluids administration to help prevent dehydration and fatigue. Currently researchers are investigating potential vaccines to reduce the chance of exposure to E. coli . There are several types of vaccines including inactivated vaccines that require several additional doses or booster shots, live attenuated, subunit, toxoid, conjugate, DNA and recombinant vector vaccines [7, 8]. The development of vaccines against diarrheagenic E. coli pathotypes represents a major challenge because of the large number of serotypes involved and the requirement to induce immunity that is effective in the gut [9, 10].
In addition, inclusion of an immunological agent that modifies the immune response of vaccine and produce long lasting immunity is needed. These adjuvants minimize the amount of injected foreign material. Some adjuvants, such as alum are approved for human use worldwide with few exceptions. The adjuvant activity of aluminum compounds was demonstrated since 1926 with diphtheria toxoid adsorbed on alum . Reports have also demonstrated that alum has limitations especially when several doses are recommended , so there is a need for novel model of adjuvants to be designed. Cholera toxin (CT) is a potent oral and parenteral immunogen, however, the toxicity associated with CT makes it an unlikely candidate for human use. The cholera toxin B subunit (CTB) has been used instead of cholera toxin as an adjuvant as B–subunit lacks toxicity, has potent biological properties and is a powerful mucosal and parenteral adjuvant that induces a strong immune response against co-administered or coupled antigens . Another difference between CT and CTB is that CT induces the release of inflammatory cytokines such as IL-6 and IL-1β, while the reverse is true with CTB that inhibit IL-6 release .
The present work aimed to develop combined inactivated vaccine candidates of five subgroups of diarrheagenic E.coli to provide wide protection against different pathotypesof E. coli. In addition, we compared the potentials of alum and cholera toxin B subunit as adjuvants in augmenting humoral immune response to candidate E. coli vaccine. The results showed that candidate combined vaccine was safe and effective in protection against living E. coli. Thus giving promising results in stimulating humoral immune responses in mouse model. We also found that CTB elicited a significant increase in the immune response as compared with alum, suggesting better response as adjuvant.
Mice immunized with combined candidate E. coli vaccine exhibited 100 % survival when challenged with living E. coli
We evaluated the immune efficacy of adjuvanted and unadjuvanted formalin-killed whole-cell combined E. coli vaccine candidate by comparing survival of pre-immunized mice following challenge with living E. coli. We immunized twice Balb/C mice (n = 5 mice/group) subcutaneously with 109 CFUs of unadjuvanted, alum-adjuvanted or CTB-adjuvanted formalin-killed whole-cell vaccine candidates. Combined vaccine candidate consisted of the five main pathotypes of diarrheagenic E. coli we formulated. We also immunized mice using the five different individual E. coli pathotypes, EAEC, EPEC, EIEC, EHEC, and ETEC. Formalin served as vehicle controlin addition to PBS control group, for a total of 20 groups (n = 5 mice per group) (Table 1). Two weeks after immunization, mice groups were challenged intraperitoneally with 106 CFU of respective living E. coli pathotypesor combination of the five E. colipathotypes.We found that the combined vaccine candidate whether adjuvanted or not showed 100 % survival rate post challenge compared to unimmunized controls (p < 0.0001) (Fig. 1). Similar responses were observed with 100 % survival ratein mice immunized with each CTB- adjuvanted E. coli pathotypes (Fig. 1c). However, survival rate of mice immunized with unadjuvanted or alum-adjuvanted individual E. coli pathotypes ranged between 50 and 100 % depending on the adjuvant (Fig. 1).
Survival rates were different depending on adjuvant (Fig. 1) therefore we analyzed the effect of adjuvantson mice survival rate post challenge. We found that CTB showed 100 % survival compared to alum and unadjuvanted vaccine candidates (Fig. 2). For each vaccine candidate, we compared survival rates of unadjuvanted, CTB and alum-adjuvanted candidates. We found that there was no difference in survival of mice immunized with either unadjuvanted, CTB or alum adjuvanted combined vaccine candidate, with 100 % survival (Fig. 2a). Similarly, different adjuvant systems showed similar survival rates (100 %) in mice immunized with individual EAEC and EPEC pathotypes (Fig. 2b, c). However, mice immunized with CTB-adjuvanted EHEC and ETECpathotypes showed higher survival rates than alum and non-adjuvanted vaccines (Fig. 2e, f). Both adjuvant systems used offered better protection than unadjuvanted EIEC (Fig. 2d). In general, combined vaccine candidate showed 100 % survival rate irrelevant of adjuvant system used, offering protection from all five main pathotypesof diarrheagenic E. coli in a single dose.
We also immunized Balb/c mice using oral gavage with ~2 × 109 CFU of combined vaccine. Two control groups received sodium bicarbonate vehicle and formalin orally. One week later, we challenged the mice with ~2 × 108 CFU of living combined E. coli by oral route. We observed mice groups daily for 1 week post challenge and found that immunized mice did not develop diarrhea and survived challenge compared to controls (p < 0.0001) (Additional file 1: Figure S1).
Candidate vaccine elicits specific systemic antibodies in sera of immunized mice
With 100 % survival post challenge of immunized mice, we aimed to assess in vivo specific humoral immune responses. We used mouse model immunized subcutaneously with 109 CFU of respective formalin-killed whole-cell diarrheagenic E. coli. Mice (n = 10 per group) were then challenged intraperitoneally with 106 CFU of respective living diarrheagenic E. coli. Post-challenge specific IgG absorbance values against respective E. coli antigens were significantly higher in mice immunized with combined vaccine candidate than those immunized with individual E. coli pathotypes (p < 0.05) (Fig. 3, Additional file 2: Figure S2 and Additional file 3: Figure S3). An exception was mice immunized with EIEC alum adjuvanted and ETEC non-adjuvanted although showed higher IgG absorbance values; however did not reach significance (Additional file 2: Figure S2C and 2E).
We also monitored specific IgG antibody response over 6 weeks period post immunization with respective formalin-killed whole-cell vaccine. We selected time points 7, 14, 21, 28, 42 days to evaluate sustainability of immune response elicited by different diarrheagenic E. coli pathotypes in comparison to combined vaccine candidate. We found a general pattern of increase in specific IgG absorbance values compared to individual E. coli pathotypes at most time points (p < 0.05) (Fig. 3; Additional file 2: Figure S2 and Additional file 3: Figure S3). Details of exceptions to the pattern were mice immunized with CTB-adjuvanted EAEC showed comparable IgG absorbance values to combined vaccine at all time points prior to challenge (Fig. 3a). Mice immunized with alum-adjuvanted EAEC showed comparable absorbance values of IgG to combined vaccine candidate at 21, 28 and 42 days prior to challenge (Additional file2: Figure S2A) and those immunized with unadjuvanted EAEC had similar absorbance values to the combined candidate at 21 and 28 days post immunization (Additional file 3: Figure S3A). Another exception was EPEC unadjuvanted and alum adjuvanted showed comparable absorbance values of IgG to the combined vaccine at some of the time points measured (Additional file 2: Figure S2B and Additional file 3: Figure S3B). EIEC, EHEC and ETEC alum adjuvanted antigens showed comparable IgG absorbance values to combined vaccine candidate at 21, 28 and 42 h post immunization (Additional file 2: Figure S2C). In general, CTB-adjuvanted combined vaccine candidates elicited significantly higher sustained specific immunoglobulin absorbance values over 6 weeks than individual E. coli antigens.
CTB-adjuvanted candidate vaccine elicits highest response of specific antibodies in sera of immunized mice
To analyze adjuvant system immune efficacy in our combined candidate vaccine for diarrheagenic, we compared the effects of CTB and alum on absorbance values of IgG post immunization with formalin-killed whole-cell E. coli in Balb/C mouse model. We immunized mice with formalin-killed whole-cell E. coli pathotypes and combined vaccine (109 CFU). We monitored serum absorbance values of IgG every week for 6 weeks post immunization. At week 7, we challenged mice with respective living E. coli pathotype (106 CFU) and measured specific IgG absorbance values post challenge. We found in general that CTB elicited significantly higher sustained immune response over 6 weeks after immunization. When the mice were challenged with the living strains, we found increase in the immune response than before challenge with the different pathotypes. CTB achieved overall higher significance than alum and unadjuvanted vaccine candidate post challenge, but elicited comparable immune response against alum with combined candidate, EIEC and ETEC (Fig. 4a, d, f).
Candidate vaccine stimulates pro-inflammatory cytokines production in sera of immunized mice
We analyzed selected pro-inflammatory cytokines levels in sera of mice immunized with each pathotype and the combined five pathotypes, whether adjuvanted with CTB or alum. We found that in general, adjuvanted antigens elicit higher levels of the measured pro-inflammatory cytokines (Figs. 5 and 6). IFNγ sera levels in mice immunized with CTB-adjuvanted antigens were significantly higher than alum-adjuvanted antigens (Fig. 6). Meanwhile,IL-6 levels elicited by CTB-adjuvanted antigens were as low as diluent assay and lower than either unadjuvanted or alum-adjuvanted antigens. This is due to inhibitory effect of CTB on IL-6 production reported in several mice models [14–16]. Meanwhile, IL-6 levels elicited by candidate vaccine whether unadjuvanted or alum-adjuvanted were significantly higher than the each E. coli pathotype (Fig. 7 and Additional file 4: Figure S4). This is especially true during the first 2 weeks after immunization and post challenge except for ETEC (Fig. 7f). We also found that serum levels of pro-inflammatory IFNγ in mice immunized with either non-adjuvanted, CTB or alum adjuvanted were significantly higher in response to combined antigens than individual antigens (p < 0.05, 0.001 and 0.0001) (Fig. 8, Additional file5: Figure S5, and Additional file 6: Figure S6).
Enteric and diarrheal diseases are a major cause of childhood death in the developing world, ranking second cause of death in children under 5 years old . Due to high mortality, several international organizations such as WHO and UNICEF have dedicated preventive and control programs for diarrheal diseases. Prevention methods include vaccines and improvement in water supplies, hygiene and sanitation. Among the leading causes of diarrhea is E. coli. Infection with various pathotypes of E. coli causes a high percentage of death in children under 5 years old in the developing world. ETEC diarrheal infection alone is responsible for 1.3 million-death cases annually .
There have been successful trials for development of vaccines to individual pathotypes of E. coli; these vaccine candidates are reviewed in [19–21]. Despite these successful vaccine trials, there is no single vaccine available for all the different types of E. coli causing diarrhea. Combination vaccines have several advantages including reducing the cost of manufacturing separate vaccines and extra health care visits. Having one combined vaccine improves timeliness of vaccination as some parents and health care providers raised objections to administering multiple injections during a single visit. This is considered a major advantage of combined vaccines . Several combination vaccines have achieved great success in immunization as MMR and DTP, encouraging formulating combination vaccine for E. coli. Dukoral is an example of successful combined whole cell killed cholera vaccine available in market. It consists of mixture of four preparation of whole cell inactivated Vibrio cholera O1 (Inaba and Ogawa serotypes, classical and El Tor biotypes) with recombinant CTB . We took into consideration the advantages of combined vaccines and designed our candidate-combined vaccine of different diarrheagenic E. coli pathotypes. Our candidate vaccine induced humoral immune response at measured time points offering protection against diarrhea in tested murine model. Mice immunized with our candidate combined diarrheagenic E. coli vaccine showed marked survival rate post challenge compared to control groups. In addition, high specific antibodies responses to each antigen were elicited post immunization of mice and at selected time points and post challenge.
There is a possible relationship between the maintenance of specific antibody response post immunization with inactivated whole-cell E. coli mixture and B cell mediated memory response to challenge with living bacteria [21, 24]. This is evident in our study where, stimulation of the immune response via immunization with combined vaccine containing inactivated whole-cells of the five main E. coli pathotypes led to production of specific IgG in immunized mice. This specific IgG response was sustained over the period of 6 weeks post immunization (Fig. 4). Due to specific B-cell memory immune responses, this specific IgG was significantly high post challenge. Specific IgG response in combination with production of IFNγ conferred protection from diarrhea (Figs. 4, 6, 8). Thus resulting in significantly higher survival (100 %) of the immunized mice compared to controls (P < 0.005) (Fig. 2). Adjuvant systems used in this study, alum and CTB, have potentiated action of the antigen. Due to variations in adjuvant nature of alum and CTB, where CTB in itself is immunogenic, thus induced higher immune response than alum post immunization. In addition, CTB maintained a good level of specific antibodies than alum (Fig. 4). Mean while, post challenge, there was no significant difference between CTB and alum as adjuvant systems in the specific IgG response except in EHEC, EAEC and EPEC where CTB induced the highest response (Fig. 4). This might be due to the excellent adjuvant effect of both CTB and alum, however the exact reason might need further investigation.
We also demonstrated that there was a significant increase in relevant cytokines levels post immunization. These are important features to any effective vaccine candidate where specific response was attained. Developments of vaccines against various pathotypes of E. coli using animal models have usually used specific subunits, toxins, secreted, or recombinant proteins offering significant protection [25–30]. The use of specific subunits, toxins or recombinant proteins offers significant protection and has been critical in recent advances in vaccines development. However, we chose to use whole–cell vaccine due to several reasons. One of these reasons is that preparation of whole-cell vaccines is easy and of low-cost, making such a vaccine cost-effective and very useful for poor countries where diarrhea is a critical health problem among infants and children [31, 32]. Additionally, oral ETEC whole-cell vaccines have been proven safe and effective in immunizing infants and children in clinical trials. In addition, oral whole-cell typhoid vaccine, Ty2a, has proved to be effective, safe and immunogenic offering protection from typhoid. Moreover, we aimed to offer wide-protection by combining major pathotypes of diarrheagenic E. coli and having all antigens of a whole-cell vaccine. Thus, our candidate combined vaccine is simple to prepare in addition it offers both efficacy and cost-effectiveness.
Dosing is another important consideration when formulating E. coli vaccines. Usually several doses are needed to maintain an efficient immunity. This would be an economical burden for developing countries where diarrhea caused by E. coli is prevalent. To overcome this limitation, vaccines are formulated with adjuvants that stimulate the immune response at either the cellular or humoral level and generate a depot effect, by stimulating a granuloma around the antigen. However, the choice of an appropriate adjuvant requires careful considerations . One of the commonly used adjuvants in human vaccination is alum. Alum is found in numerous vaccines, including diphtheria-tetanus-pertussis, human papillomavirus and hepatitis vaccines . Alum provokes a strong Th2 response, but it is rather ineffective against pathogens that require Th1–cell-mediated immunity . However, alum has several side effects when high doses of vaccines are required. High levels of alum in the body affect multiple organs causing brain and bone tissue damage leading to fatal neurological syndrome . Another commonly used adjuvant is cholera toxin (CT). CT has immune modulatory effects on different cell types; the interaction of CT with dendritic cells may be critical for its adjuvant activity [36, 37]. In addition, CT augments cellular immune responses of co-administrated antigens eliciting the production of IL-4, IL-5 and IL-10 . B-subunits of CT are the commonly used form of CT in enhancing the immune response to conjugated antigens [38–44]. All these immunogenic effects of adjuvants make their choice an important consideration in vaccine development. Therefore, another aim of our work was to study the effect of adjuvants on the immune response of whole cell formalin killed diarrheagenic.
Our results showed a significant increase in the immune responses associated with the whole cell formalin inactivated E. coli combined with cholera toxin B subunit than that achieved with alum. IFNγ levels increased after immunization whether using CTB or alum in agreement with previous studies [45, 46]. However, we found that CTB-adjuvanted vaccine candidates elicited a significant increase in IFNγ level than that detected with alum. The reverse was observed withIL-6, where alum increased the concentration of IL-6, but CTB did not affect its secretion in agreement with [14–16]. This is due to possible inhibitory effects of CTB on both B cell dependent and independent pathways for IL-6 production [15, 16].
Survival rate after mice challenge is used to evaluate the efficacy and safety of the formulated vaccine candidates. Our results showed that the survival rate after immunization with vaccine candidate whether non-adjuvanted or adjuvanted was significantly higher than the controls. However, on comparing selected adjuvants, we found that survival rate post immunization with CTB-adjuvanted vaccine was higher than alum. Collectively, our results suggested that CTB-adjuvanted combined vaccine had more advantages than alum adjuvanted as far as protection, eliciting immune responses and survival rates.
Finally, we aimed to assess involvement of immune cell populations in protection, we analyzed cell populations post immunization and challenge in mice groups. Different E. coli pathotypes have been reported to induce mucosal inflammatory responses with infiltration of neutrophils to site of infection [47–49]. However, in our model of combined vaccine candidate, we found that NLR (neutrophil lymphocyte ratio) did not significantly differ from the controls and this is in agreement with  where killed bacterial vaccines usually do not elicit migration of neutrophils.
We developed and tested a new combined vaccine in mice, alone and with an adjuvant system. The vaccine contained E. coli main five diarrheagenic pathotypes ETEC, EHEC, EIEC, EAEC and EPEC. Immunization of mice induced serum antibody responses to all antigens in the combined vaccine. In addition, immunized mice had protective pro-inflammatory responses and higher survival rates post challenge. These responses were further enhanced by adjuvant systems whether alum or CTB. We found that CTB was a better adjuvant to our vaccine candidate than alum. The vaccine, both with and without adjuvants, was stable and well tolerated. Our ongoing studies focuses on formulating our candidate vaccine as oral instead of subcutaneous vaccine. A change in route of vaccine administration is anticipated to be successful as there have been several oral vaccine trials that proved safe and immunogenic using various E. coli diarrheagenic pathotypes, for example ETEC/rCTB [31, 32]. Our candidate vaccine offers protection against the five main diarrheagenic E. coli in a single dose. However, vaccination might affect gut flora in human beings and it would be interesting to see if our candidate combined vaccine might affect gut microbiota prior to clinical trials. In addition, further studies on extended immunity and clinical studies in humans would be valuable.
Bacterial strains and culturing conditions
We used standard reference strains of Enteroaggregative E.coli (EAEC) (RKI 17-2), Enteroinvasive E. coli (EIEC) ATCC 43893 (O124:NM, USA), and Enterohaemorrhagic E. coli (EHEC) ATCC 43890 (O157:H7). In addition, reference strains of Enterotoxigenic E. coli (ETEC) and Enteropathogenic E. coli (EPEC) were kindly provided by Dr. Marwa E.A. Aly [51, 52].
Escherichia coli were cultured in Luria Broth (LB) (Difco, Sparks, MD, USA) at 37°c for 14 h and harvested with phosphate buffer saline (PBS) (Bio Basic Inc., Ontario, Canada). Cells were washed in PBS by centrifugation at 500×g for 10 min at 4°c . The concentration of E. coli was adjusted at 109 CFU/ml. Formalin (Fischer-scientific, Leicestershire, UK) was then added (0.4 %) to kill E. coli. The formalin treated bacteria was kept for 24 h to ensure killing action of the formalin. Formalin-treated bacterial suspensions were confirmed dead as there was no living microorganisms found on inoculating the suspensions in LB. The killed organisms were harvested by centrifugation at 6000×g for 1 h at 4°c then washed twice with sterile PBS (pH 7.2). The pellets obtained were re-suspended in PBS. We performed sterility testing of prepared formalin inactivated vaccine to check if there was contamination by other bacteria. Sterility test was done by taking a loop full of the prepared formalin killed antigen onto blood agar, McConkey agar plates and thioglycollate broth (Sigma Aldrich, Saint Louis, MO, USA) and incubating for 24–48 h at 37° .
We prepared Aluminum phosphate (alum) (Sigma Aldrich, Saint Louis, MO, USA) by preparing 0.63 M AlCl3.6H2O and sodium phosphate solution(0.3 M Na3PO4.12 H2O)each in 40 ml saline and sterilized by filtration. Final alum adjuvant was prepared according to the method detailed in [12, 55, 56]. Recombinant CTB (rCTB) was kindly provided from the Holding Company for Biological Products and Vaccines (VACSERA, Giza, Egypt).
Balb/C male and female mice, 6–8 weeks old were used for all experiments. The mice were purchased from VACSERA to Helwan (VACSERA vivarium, Helwan, Egypt). Animals were housed in accordance with standard laboratory conditions with access to food and water ad libitum, in an environmentally controlled room with 12 h light and dark cycles. A total of 325 mice were used in this study to determine effect of combined candidate vaccine on survival post-challenge and immunological response of mice to the candidate vaccine.
All animal experiments were conducted in accordance with the institutional regulations. The Institutional Ethical Committee of the Faculty of Pharmacy, Cairo University, Egypt, approved animal studies (approved protocol number MI (737)).
Balb/C mice (n = 5 mice/group, for a total of 125 mice) were double immunized one-week apart subcutaneously with 109 CFU of respective unadjuvanted, alum–adjuvanted or CTB-adjuvanted formalin–killed whole–cell combined vaccine candidate (Table 1). We also immunized the mice with each of the five main diarrheagenic E. coli pathotypes, EAEC, EPEC, EIEC, EHEC, and ETEC. Formalin served as vehicle control in addition to PBS control group, for a total of 25 groups (Table 1). After 2 weeks the mice were injected the challenge dose 106 CFU (0.5 ml) of respective E. coli pathotype intraperitoneally and the mice were observed for 7 days and the rate of survival was determined .We tested our candidate vaccine using oral route by immunizing Balb/c mice by oral gavage with ~2 × 109 CFU of combined vaccine in 300 μl of sodium bicarbonate twice 1 week apart. Two control groups received orally 300 μl of sodium bicarbonate vehicle and formalin. We observed mice daily for 1 week then the mice were challenged with ~2 × 108 CFU of living combined E. coli pathotypes by oral route. We observed mice groups daily for 1-week post challenge.
Assessment of immunological response patterns of the candidate vaccine
We immunized Balb/C mice (n = 10 per group) subcutaneously with 109 CFU of respective formalin-killed whole-cell diarrheagenic E. coli pathotypes (Table 2). We collected blood from mice to monitor the immune responses weekly for 6 weeks. At week 7, mice were then challenged intraperitoneally with 106 CFU of respective living diarrheagenic E. coli pathotype and monitored for one-week post challenge. Control groups included CTB, alum, formalin and PBS (n = 5 per control group), for a total of 200 mice used in immunological response assessment experiments. All control groups were challenged with combined candidate vaccine (Table 2).
Detection of antibodies against E. coli antigen
We collected blood samples weekly throughout the experiment via retro-orbital plexus of immunized mice groups (Table 2). Sera were collected by cold centrifugation for 15 min at 5000 rpm. Enzyme Linked Immunosorbent assay (ELISA) plates (Nunc-Denmark) were coated with whole-cell inactivated E. coli antigen in carbonate-bicarbonate buffer (Sigma Aldrich, Saint Louis, MO, USA), pH 9.6 as 100 µl/well(6 µg/ml) and the experiment was processed according to established previous studies [58–60]. Sera from two mice per group were pooled and assessed for a total of five mice pools per group.
We measured levels of pro-inflammatory cytokines in sera of mice groups (Table 2).We pooled sera of five mice per group prior to assay and assessed levels of IL-6 and IFNγ using ELISA method according to the manufacturer’s protocol (BiooScientific Co., Austin, TX, USA). Concentrations were calculated based on standard curve analysis (Additional file 7: Figure S7).
Complete blood count analysis
We collected blood from mice in EDTA-coated tubes and analyzed percentages of neutrophils and lymphocyte using slide method. We calculated neutrophils lymphocyte ratio. All samples were compared to the control groups.
Data were analyzed using GraphPad Prism 6.01 (GraphPad Software Inc., California, USA). We used analysis of variance (one way analysis of variance (ANOVA)) for comparison of cytokine and antibody levels means. Statistical analyses for comparison of antibody absorbance values or cytokine levels elicited by combined candidate vaccine and each of E. coli antigens was calculated using unpaired Student’s t-test. Significance testing for comparison of survival curves was done using Log-rank (Mantel- Cox)test. p less than 0.05 were considered significant.
analysis of variance
colony forming unit
cholera toxin subunit B
enteroaggregative Escherichia coli
enterohemorrhagic Escherichia coli
enteroinvasive Escherichia coli
enzyme Linked Immunosorbent assay
enteropathogenic Escherichia coli
enterotoxigenic Escherichia coli
phosphate buffer saline
recombinant cholera toxin subunit B
Steffen R, Castelli F, Nothdurft HD, Rombo L, Zuckerman JN. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers’ diarrhea. J Travel Med. 2005;12(2):102–7.
Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004;2(2):123–40. doi:10.1038/nrmicro818.
Torres AG, Zhou X, Kaper JB. Adherence of diarrheagenic Escherichia coli strains to epithelial cells. Infect Immun. 2005;73(1):18–29. doi:10.1128/IAI.73.1.18-29.2005.
Okeke IN, Nataro JP. Enteroaggregative Escherichia coli. Lancet Infect Dis. 2001;1(5):304–13. doi:10.1016/S1473-3099(01)00144-X.
Harrington SM, Dudley EG, Nataro JP. Pathogenesis of enteroaggregative Escherichia coli infection. FEMS Microbiol Lett. 2006;254(1):12–8. doi:10.1111/j.1574-6968.2005.00005.x.
Qadri F, Svennerholm AM, Faruque AS, Sack RB. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev. 2005;18(3):465–83. doi:10.1128/CMR.18.3.465-483.2005.
Plotkin S. History of vaccination. Proc Natl Acad Sci USA. 2014;111(34):12283–7. doi:10.1073/pnas.1400472111.
Plotkin SA. Vaccines, vaccination, and vaccinology. J Infect Dis. 2003;187(9):1349–59. doi:10.1086/374419.
Zhang W, Zhao M, Ruesch L, Omot A, Francis D. Prevalence of virulence genes in Escherichia coli strains recently isolated from young pigs with diarrhea in the US. Vet Microbiol. 2007;123(1–3):145–52. doi:10.1016/j.vetmic.2007.02.018.
Frydendahl K. Prevalence of serogroups and virulence genes in Escherichia coli associated with postweaning diarrhoea and edema disease in pigs and a comparison of diagnostic approaches. Vet Microbiol. 2002;85(2):169–82.
Glenny A, Pope C, Waddington H, Wallace U. Immunological notes. XVII–XXIV. J Pathol. 1926;29:31–40. doi:10.1002/path.1700290106.
Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998;32(3):155–72.
Loc NH, Yang M-S, Kim T-G. Highly expressed cholera toxin B subunit in the fruit of a transgenic tomato (Lycopersicon esculentum L.). Biotechnol Bioprocess Eng. 2011;16(3):576–80.
Leal-Berumen I, Snider DP, Barajas-Lopez C, Marshall JS. Cholera toxin increases IL-6 synthesis and decreases TNF-alpha production by rat peritoneal mast cells. J Immunol. 1996;156(1):316–21.
Sun JB, Raghavan S, Sjoling A, Lundin S, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3 + CD25 + and Foxp3-CD25-CD4 + regulatory T cells. J Immunol. 2006;177(11):7634–44.
Tarkowski A, Sun JB, Holmdahl R, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum. 1999;42(8):1628–34. doi:10.1002/1529-0131(199908)42:8<1628:AID-ANR10>3.0.CO;2-T.
Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379(9832):2151–61.
Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969–87. doi:10.1016/S0140-6736(10)60549-1.
Zhang W, Sack DA. Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines. 2012;11(6):677–94. doi:10.1586/erv.12.37.
Horne C, Vallance BA, Deng W, Finlay BB. Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines. Expert Rev Vaccines. 2002;1(4):483–93. doi:10.1586/147605184.108.40.2063.
Svennerholm AM, Lundgren A. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines. 2012;11(4):495–507. doi:10.1586/erv.12.12.
Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 Suppl):S6–12.
Lopez-Gigosos RM, Plaza E, Diez-Diaz RM, Calvo MJ. Vaccination strategies to combat an infectious globe: oral cholera vaccines. J Glob Infect Dis. 2011;3(1):56–62. doi:10.4103/0974-777X.77297.
Boll EJ, McCormick BA. A new understanding of enteroaggregative Escherichia coli as an inflammatory pathogen. Cell Adh Migr. 2012;6(5):413–8. doi:10.4161/cam.21241.
Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, Armstrong GD. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis. 2001;183(3):435–43.
Ishikawa S, Kawahara K, Kagami Y, Isshiki Y, Kaneko A, Matsui H, et al. Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infect Immun. 2003;71(6):3235–9.
Marcato P, Griener TP, Mulvey GL, Armstrong GD. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. Infect Immun. 2005;73(10):6523–9.
Asper DJ, Karmali MA, Townsend H, Rogan D, Potter AA. Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans. Clin Vaccine Immunol. 2011;18(7):1052–7.
Liu J, Sun Y, Feng S, Zhu L, Guo X, Qi C. Towards an attenuated enterohemorrhagic Escherichia coli O157: h7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins. Vaccine. 2009;27(43):5929–35.
Torres AG. Intestinal pathogenic Escherichia coli. In: Barrett ADT, Stanberry LR, editors. Vaccines for biodefense and emerging and neglected diseases. London: Academic Press; 2009. p. 1013–29.
Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF Jr, et al. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J. 2002;21(4):322–30.
Savarino SJ, Hall ER, Bassily S, Brown FM, Youssef F, Wierzba TF, et al. Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. J Infect Dis. 1999;179(1):107–14. doi:10.1086/314543 (PRIDE Study Group).
Delamarre L, Couture R, Mellman I, Trombetta ES. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med. 2006;203(9):2049–55. doi:10.1084/jem.20052442.
Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287–93. doi:10.1038/nri2510.
Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–96.
Anjuere F, Luci C, Lebens M, Rousseau DB, Hervouet C, Milon GV, et al. In vivo adjuvant-induced mobilization and maturation of gut dendritic cells after oral administration of cholera toxin. J Immunol. 2004;173(8):5103–11.
Gagliardi MC, Sallusto F, Marinaro M, Vendetti S, Riccomi A, De Magistris MT. Effects of the adjuvant cholera toxin on dendritic cells: stimulatory and inhibitory signals that result in the amplification of immune responses. Int J Med Microbiol. 2001;291(6):571–5.
Weltzin R, Guy B, Thomas WD Jr, Giannasca PJ, Monath TP. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun. 2000;68(5):2775–82.
Isaka M, Zhao Y, Nobusawa E, Nakajima S, Nakajima K, Yasuda Y, et al. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice. Microbiol Immunol. 2008;52(2):55–63. doi:10.1111/j.1348-0421.2008.00010.x.
Maeyama J, Isaka M, Yasuda Y, Matano K, Morokuma K, Ohkuma K, et al. Effects of recombinant cholera toxin b subunit (rCTB) on cellular immune responses: enhancement of delayed-type hypersensitivity following intranasal co-administration of Mycobacterium bovis-BCG with rCTB. Microbiol Immunol. 2004;48(6):457–63.
Isaka M, Komiya T, Takahashi M, Yasuda Y, Taniguchi T, Zhao Y, et al. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine. 2004;22(23–24):3061–8. doi:10.1016/j.vaccine.2004.02.019.
Yasuda Y, Isaka M, Taniguchi T, Zhao Y, Matano K, Matsui H, et al. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies. Vaccine. 2003;21(21–22):2954–63.
Isaka M, Yasuda Y, Taniguchi T, Kozuka S, Matano K, Maeyama J, et al. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine. 2003;21(11–12):1165–73.
Maeyama J, Isaka M, Yasuda Y, Matano K, Kozuka S, Taniguchi T, et al. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Microbiol Immunol. 2001;45(2):111–7.
George-Chandy A, Eriksson K, Lebens M, Nordstrom I, Schon E, Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect Immun. 2001;69(9):5716–25.
Aramaki Y, Suda H, Tsuchiya S. Interferon gamma inductive effect of liposomes as an immunoadjuvant. Vaccine. 1995;13(18):1809–14.
Boll EJ, Struve C, Sander A, Demma Z, Krogfelt KA, McCormick BA. Enteroaggregative Escherichia coli promotes transepithelial migration of neutrophils through a conserved 12-lipoxygenase pathway. Cell Microbiol. 2012;14(1):120–32. doi:10.1111/j.1462-5822.2011.01706.x.
Ramos CD, Fernandes KS, Canetti C, Teixeira MM, Silva JS, Cunha FQ. Neutrophil recruitment in immunized mice depends on MIP-2 inducing the sequential release of MIP-1alpha, TNF-alpha and LTB(4). Eur J Immunol. 2006;36(8):2025–34. doi:10.1002/eji.200636057.
Williams MR, Azcutia V, Newton G, Alcaide P, Luscinskas FW. Emerging mechanisms of neutrophil recruitment across endothelium. Trends Immunol. 2011;32(10):461–9. doi:10.1016/j.it.2011.06.009.
Rose R, Moon HW. Elicitation of enteroluminal neutrophils by enterotoxigenic and nonenterotoxigenic strains of Escherichia coli in swine. Infect Immun. 1985;48(3):818–23.
Aly MEA, Essam TM, Amin MA. Involvement of virulence genes and antibiotic resistance in clinical and food borne diarrheagenic Escherichia coli isolates from Egypt. World J Med Sci. 2012;7(4):276–84.
Aly ME, Essam TM, Amin MA. Antibiotic resistance profile of E. coli strains isolated from clinical specimens and food samples in Egypt. Int J Microbiol Res. 2012;3(3):176–82.
Lim SY, Bauermeister A, Kjonaas RA, Ghosh SK. Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. J Immune Based Ther Vaccines. 2006;4:5. doi:10.1186/1476-8518-4-5.
WHO. General requirements for the sterility of biological substances Journal. 1973;2015(Issue):Revised 1973, TRS No 530, Annex 4.
Burrell LS, Lindblad EB, White JL, Hem SL. Stability of aluminium-containing adjuvants to autoclaving. Vaccine. 1999;17(20–21):2599–603.
Lindblad EB. Aluminium adjuvants–in retrospect and prospect. Vaccine. 2004;22(27–28):3658–68. doi:10.1016/j.vaccine.2004.03.032.
Melikova EN, Lesnjak SV. International reference preparations of typhoid vaccine. Potency assay by the active mouse protection test with three different routes of immunization. Bull World Health Organ. 1967;37(4):575–9.
Guerena-Burgueno F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun. 2002;70(4):1874–80.
Jertborn M, Ahren C, Holmgren J, Svennerholm AM. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. Vaccine. 1998;16(2–3):255–60.
Svennerholm AM, Holmgren J, Black R, Levine M, Merson M. Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis. 1983;147(3):514–22.
Conceived and designed the experiments: MAANFA AG Performed the experiments: AG Analyzed the data: NFA AG Contributed reagents/materials/analysis tools: MAA AF AG NFA. Wrote the paper: NFA AG. All authors read and approved the final manuscript.
The authors would like to thank Dr. Mohamed Rabiae, vaccine production manager in VACSERA, for providing technical advice. We would like to thank Dr. Marwa E.A. Aly, researcher at Biotechnology Centre, Faculty of pharmacy, Cairo University, for providing enterotoxigenic and enteropathogenic pathotypes strains.
The authors declare that they have no competing interests.
About this article
Cite this article
Gohar, A., Abdeltawab, N.F., Fahmy, A. et al. Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model. BMC Res Notes 9, 80 (2016) doi:10.1186/s13104-016-1891-z
- Escherichia coli
- Whole-cell vaccine
- Interleukin 6
- Interferon gamma
- Adjuvant system
- Cholera toxin subunit B